Key Takeaways
- Steady domestic engine, acute softness: Domestic business grew 9% YoY with chronic portfolio up over 20%, while a muted acute season weighed on legacy brands like Metrogyl and Rantac.
- Margins expanded on mix and cost control: Gross margin rose 200 bps to 68.2% and operating margins benefited from contained overheads, keeping the company comfortably inside its guided bands.
- International was a tale of two halves: Russia and CDMO each grew 20%, but South Africa’s shift from public tender to private market and a high US base suppressed overall international formulations growth to just 2%.
- Ophthal license reset is a known, dated catalyst: The perpetual license triggers in December 2026; from CY27 the portfolio consolidates with a margin profile management says will exceed the standalone domestic business.
- What to watch next quarter: Whether the promised H2 bounce in US and international formulations materializes, the pace of South Africa’s private-market transition, and any pickup in the acute season.
Domestic Business
- Volume leadership holds: Volume growth was 4% against IPM volume growth of 0.5% to 0.7%, sustaining the commitment to grow at least 3 percentage points above market volume. Price contributed 6% and new introductions a non-significant portion.
- Chronic portfolio the star: Chronic brands grew over 20%, driving overall performance even as the acute season stayed muted. The Reserve Franchise (Rosuvastatin) crossed INR100 crore in MAT September 2025, up from INR66 crore in MAT September 2022.
- Legacy brands a drag: Rantac and Metrogyl showed slightly muted growth trends, a direct consequence of the soft acute season, and this pulled the overall domestic growth rate to 9%.
- Brand rank momentum: All major brands gained ranks; three brands now sit in the top 100 in IPM and six in the top 300.
- Ophthalmology building a base: Prescriber expansion and new organic launches in the age of trails are showing good traction, with improved coverage in the ophthalmology doctor community widening the prescriber base ahead of the license consolidation.
- MR productivity as a gating item: Field force stands at roughly 2,400 active MRs on the ground (the earlier ~2,800 figure included managers). Management will consider adding to the field force only once productivity touches an internal aspiration of INR8 lakh.
Chopra: "We have taken an internal aspiration that we would like to at least touch INR8 lakh productivity, which would be a good productivity for the portfolio mix that we have got."
International Formulations
- Russia and CDMO delivered, South Africa and US did not: Russia grew in high teens (roughly 20%) and CDMO grew 20%, but South Africa was subdued by a structural shift from public tender (down to 35% of the business from 65% two years ago) to private market, while the US faced a high base from prior-year supply. Overall international formulations grew only 2%.
- South Africa’s pivot is deliberate: Management expressed confidence in propelling growth in the private market, framing the tender-to-private shift as a transition rather than a loss.
- US bounce expected in H2: Growth is expected to return in Q3 and Q4; no pricing pressure was flagged in the US market.
- CDMO order book supports the second half: A robust pipeline of products for global partners and a strong order book underpin the expectation of 12% to 14% full-year CDMO growth, with H1 already at 14%.
- API business steady-state: The focus is on maximizing the market with the current portfolio and serving captive requirements, not on new launches. Management wants to maintain a quarterly run rate of INR25 crore.
Margins & Cost Structure
- Gross margin up 200 bps: Reached 68.2% in Q2, driven by cost optimization, favorable product mix, and price growth. The company reiterated its guided range of 67% to 69%.
- Overheads contained: Employee costs and other overheads were kept in check, aiding operating margin. The only one-off callout was an INR15 crore charge in Q1 related to the merger scheme, which sits outside H1 operating EBITDA.
- ESOP charge ahead: An INR10 crore ESOP charge is expected in Q3.
- Ophthal margin tailwind is dated but unquantified: From calendar year 2027, when the perpetual license triggers and the portfolio consolidates, management expects a significant improvement in the overall gross margin profile, stating it will probably be higher than the standalone domestic business’s current margin profile. No number was given.
Khanna: "We do not want to significantly peg any number or give any guidance. But just to give you a sense that even our Ophthal portfolio, the overall margin profile will be probably higher than our standalone domestic business current margin profile as well."
Capex & Infrastructure
- New IV line near commissioning: Greenfield capex is largely attributed to a new IV line, which will be commissioned within the next two months.
- Inventory levels range-bound: Management intends to continue with current inventory levels, which have been stable from Q1 and Q2.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic revenue growth | 12% to 14% growth, outpacing IPM by 300–400 bps | Ongoing |
| Volume growth vs IPM | At least 3 percentage points above IPM volume growth | Ongoing |
| Gross margin | Maintain 67% to 69% range | Ongoing |
| EBITDA margin | Maintain 27% to 29% range | Ongoing |
| International formulations growth | High single-digit growth | H2 FY26 |
| US business recovery | Growth to bounce back | Q3 and Q4 FY26 |
| CDMO full-year growth | Close to 12% to 14% | FY26 |
| API quarterly run rate | Maintain INR25 crore | Ongoing |
| Ophthal portfolio consolidation | Margin profile higher than standalone domestic business | From CY27 |
| MR field force addition | Only after productivity touches INR8 lakh | No date |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹1,085 cr, up 8% YoY |
| Domestic formulation revenue | ₹644 cr, up 9% YoY |
| International business revenue | ₹441 cr, up 7% YoY |
| CDMO revenue | ₹113 cr, up 20% YoY |
| International formulations revenue | ₹306 cr, up 2% YoY |
| API revenue | ₹22 cr, vs ₹19 cr in Q2 FY25 |
| Gross margin | 68.2%, up 200 bps YoY from 66.2% |
| Operating EBITDA (excl. non-cash ESOP) | ₹319 cr, up 12% YoY |
| Operating EBITDA margin | 29.4%, up 100 bps YoY |
| Net profit | ₹208 cr, up 19% YoY |
| H1 FY26 operating cash flow | ₹363 cr |
| Net cash and equivalents (incl. mutual funds) | ₹939 cr as of 30 Sep 2025 |
| Gross debt | ₹7 cr as of 30 Sep 2025, vs ₹14 cr on 31 Mar 2025 |
| H1 FY26 net capex addition | ₹46 cr, vs ₹49 cr in H1 FY25 |
| Domestic business volume growth | 4% for Q2; price growth 6% |
| IQVIA MAT Sep 2025 growth vs IPM | 12% company growth vs 8% IPM growth |
| MR count | ~2,400 active on ground |
| MR productivity | ~₹7.5 lakh |
| Ophthal portfolio monthly run rate | ~₹17–18 cr |
| Ophthal portfolio growth in covered markets | ~16%, vs market growth of ~8% |
| Remaining ESOP charge | ₹47 cr total; ₹20 cr in FY26, ₹27 cr in FY27 |
| Full-year capex guidance | ~₹100 cr; maintenance capex ₹60–65 cr |